Tag Archives: Cancer

Options for Oncologists Get Tougher

How does the business of oncology practice fare today? The National Comprehensive Cancer Care Network (NCCN), which allies 21 of the world’s leading cancer care and research centers in developing state-of-the-art practice guidelines, decided to ask that question in a survey it conducted among several hundred oncology specialists earlier this year. The results, a sobering […]
Posted in Strategy | Also tagged , | 2 Comments

Advisory Panel Rejects Avastin For Breast Cancer Treatment

An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger […]
Posted in FDA, Safety | Also tagged , , , , , , , | 1 Comment

Avastin Study Shows Promising Data for Cancer Patients

Genentech released the results of its Phase III Avastin study showing that women that take the ovarian cancer treatment in tandem with chemotherapy had a 39 percent improvement in the likelihood of living longer without the disease worsening than patients being treated with just chemotherapy. The data was released at the annual meeting of American […]
Posted in R&D | Also tagged , , , | Leave a comment

FDA to Review Prostate Cancer Meds

Image via Wikipedia FDA, on Monday, announced that it was reviewing whether a certain class of prostate cancer drugs could lead to diabetes, stroke, death, or heart problems. The drugs in question are gonadotropin-Releasing Hormone (GnRH) agonists, marketed under a number of monikers, including Vantas and Lupron. These treatments are used to slow the growth […]
Posted in FDA, Safety | Also tagged , , , , , , | Leave a comment

Merck, Lilly, Pfizer: One for All and All for One

Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well. Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, […]
Posted in Strategy | Also tagged , , , , , , | 1 Comment
  • Categories

  • Meta